FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:138-140 January 9, 1997 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Danner, S. A. PubMed Citation

To the Editor: The human immunodeficiency virus (HIV) encodes a protease needed for the production of infectious virions. Current therapeutic strategies employ new types of inhibitors of this protease.¹ Their side effects are relatively minor, and the drugs have not been considered directly nephrotoxic. Indinavir differs from the other protease inhibitors in that a serious adverse effect, the occurrence of kidney stones, has been noted.² We describe a patient in whom direct nephrotoxic effects of indinavir appeared to develop.

The patient was a 30-year-old white woman known to be HIV-positive for six years, who was infected heterosexually. Her CD4 count . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Vidal, F., Domingo, J. C., Guallar, J., Saumoy, M., Cordobilla, B., Sanchez de la Rosa, R., Giralt, M., Alvarez, M. L., Lopez-Dupla, M., Torres, F., Villarroya, F., Cihlar, T., Domingo, P. (2006). In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells. Antimicrob. Agents Chemother. 50: 3824-3832 [Abstract] [Full Text]